Literature DB >> 34983704

Eosinophilic esophagitis in children: Updates and practical aspects of management for allergists in a non-tertiary care private practice setup.

Ejaz Yousef1, Yelena Korotkaya1, Alyson B Simpson2.   

Abstract

Background: Eosinophilic esophagitis (EoE) is a chronic immune and/or antigen-mediated disease characterized by eosinophilic infiltration of mucosa (≥15 eosinophils per high power field) without any secondary etiology. Non-immunoglobulin E mediated mechanisms predominate in EoE. Objective: This review concentrated on a stepwise approach for the allergist working in non-tertiary care private practice.
Methods: A medical literature search that focused on several areas of the latest developments in the diagnosis and management of EoE was conducted.
Results: There has been a steady increase in the prevalence and incidence of EoE. Clinical symptoms can vary from dysphagia to failure to thrive, depending on the age at presentation; some children develop adaptive behaviors to compensate for dysphagia, such as food preferences and slow eating. The diagnosis is based on a high index of clinical suspicion and is confirmed with endoscopy with biopsies after ruling out other causes of esophageal eosinophilia. Treatment options may include dietary therapy, pharmacologic therapies, or combination therapy. Therapeutic options may also include endoscopic dilation for stricturing disease.
Conclusion: Providers should be aware of recent recommendation changes in the diagnostic workup, the role of skin-prick testing, and role of the proton-pump inhibitor as first-line therapy for EoE. Also, clinicians should be aware of the emerging role of empiric dietary therapy as a preferable therapeutic option when compared with the testing-directed diet and the elemental diet. Furthermore, topical glucocorticoid therapies are available, and new developing therapies are being investigated. Reevaluation of esophageal mucosa with biopsies is required approximately 2 months after therapy for a response and after a change in therapies to confirm continued resolution.

Entities:  

Mesh:

Year:  2022        PMID: 34983704      PMCID: PMC8749246          DOI: 10.2500/aap.2022.43.210084

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  67 in total

1.  Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study.

Authors:  Tetsuo Shoda; Ting Wen; Seema S Aceves; J Pablo Abonia; Dan Atkins; Peter A Bonis; Julie M Caldwell; Kelley E Capocelli; Christina L Carpenter; Margaret H Collins; Evan S Dellon; Michael D Eby; Nirmala Gonsalves; Sandeep K Gupta; Gary W Falk; Ikuo Hirano; Paul Menard-Katcher; Jonathan T Kuhl; Jeffrey P Krischer; John Leung; Vincent A Mukkada; Jonathan M Spergel; Michael P Trimarchi; Guang-Yu Yang; Nives Zimmermann; Glenn T Furuta; Marc E Rothenberg
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-05-03

2.  Allergy tests do not predict food triggers in adult patients with eosinophilic oesophagitis. A comprehensive prospective study using five modalities.

Authors:  H Philpott; S Nandurkar; S G Royce; F Thien; P R Gibson
Journal:  Aliment Pharmacol Ther       Date:  2016-06-01       Impact factor: 8.171

3.  Critical role for adaptive T cell immunity in experimental eosinophilic esophagitis in mice.

Authors:  Anil Mishra; James Schlotman; Meiqin Wang; Marc E Rothenberg
Journal:  J Leukoc Biol       Date:  2006-12-28       Impact factor: 4.962

4.  Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.

Authors:  Jonathan M Spergel; Marc E Rothenberg; Margaret H Collins; Glenn T Furuta; Jonathan E Markowitz; George Fuchs; Molly A O'Gorman; Juan Pablo Abonia; James Young; Timothy Henkel; H Jeffrey Wilkins; Chris A Liacouras
Journal:  J Allergy Clin Immunol       Date:  2011-12-28       Impact factor: 10.793

Review 5.  Diagnosis and treatment of eosinophilic esophagitis.

Authors:  Nirmala P Gonsalves; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2020-01       Impact factor: 10.793

6.  Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.

Authors:  Ikuo Hirano; Evan S Dellon; Jennifer D Hamilton; Margaret H Collins; Kathryn Peterson; Mirna Chehade; Alain M Schoepfer; Ekaterina Safroneeva; Marc E Rothenberg; Gary W Falk; Yehudith Assouline-Dayan; Qiong Zhao; Zhen Chen; Brian N Swanson; Gianluca Pirozzi; Leda Mannent; Neil M H Graham; Bolanle Akinlade; Neil Stahl; George D Yancopoulos; Allen Radin
Journal:  Gastroenterology       Date:  2019-10-05       Impact factor: 22.682

7.  Efficacy of IgE-targeted vs empiric six-food elimination diets for adult eosinophilic oesophagitis.

Authors:  J Rodríguez-Sánchez; E Gómez Torrijos; B López Viedma; E de la Santa Belda; F Martín Dávila; C García Rodríguez; F Feo Brito; J Olmedo Camacho; P Reales Figueroa; J Molina-Infante
Journal:  Allergy       Date:  2014-05-09       Impact factor: 13.146

8.  Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children.

Authors:  Elizabeth T Schaefer; Joseph F Fitzgerald; Jean P Molleston; Joseph M Croffie; Marian D Pfefferkorn; Mark R Corkins; Joel D Lim; Steven J Steiner; Sandeep K Gupta
Journal:  Clin Gastroenterol Hepatol       Date:  2008-02       Impact factor: 11.382

9.  ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE).

Authors:  Evan S Dellon; Nirmala Gonsalves; Ikuo Hirano; Glenn T Furuta; Chris A Liacouras; David A Katzka
Journal:  Am J Gastroenterol       Date:  2013-04-09       Impact factor: 10.864

10.  Effects of allergen sensitization on response to therapy in children with eosinophilic esophagitis.

Authors:  Robert D Pesek; Mallikarjuna Rettiganti; Erin O'Brien; Sarah Beckwith; Caroline Daniel; Chunqiao Luo; Amy M Scurlock; Peggy Chandler; Rebecca A Levy; Tamara T Perry; Joshua L Kennedy; Sheva Chervinskiy; Maryelle Vonlanthen; Helen Casteel; Stephen C Fiedorek; Troy Gibbons; Stacie M Jones
Journal:  Ann Allergy Asthma Immunol       Date:  2017-07-01       Impact factor: 6.347

View more
  1 in total

1.  Evaluation and management of adverse reactions to the COVID-2019 vaccines.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2022-01-01       Impact factor: 2.587

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.